US3663175A - Method of determining hemoglobin in blood - Google Patents

Method of determining hemoglobin in blood Download PDF

Info

Publication number
US3663175A
US3663175A US78159A US3663175DA US3663175A US 3663175 A US3663175 A US 3663175A US 78159 A US78159 A US 78159A US 3663175D A US3663175D A US 3663175DA US 3663175 A US3663175 A US 3663175A
Authority
US
United States
Prior art keywords
hemoglobin
reagent
moles
acetone
cyanmeth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US78159A
Inventor
Edward L Depositar
Robert K Shipley
David T Santore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics Corp
Original Assignee
Bio Dynamics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Dynamics Inc filed Critical Bio Dynamics Inc
Application granted granted Critical
Publication of US3663175A publication Critical patent/US3663175A/en
Assigned to BOEHRINGER MANNHEIM DIAGNOSTICS, INC., A DE CORP. reassignment BOEHRINGER MANNHEIM DIAGNOSTICS, INC., A DE CORP. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BIO-DYNAMICS, INC.
Assigned to BOEHRINGER MANNHEIM CORPORATION reassignment BOEHRINGER MANNHEIM CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BOEHRINGER MANNHEIM DIAGNOSTICS, INC. A CORP. OF DE.
Assigned to BOEHRINGER MANNHEIM CORPORATION reassignment BOEHRINGER MANNHEIM CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Assignors: BOEHRINGER MANNHEIM CORPORATION, A NY CORP.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin

Definitions

  • This invention relates to a method of determining hemoglobin in blood using Drabkins reagent.
  • the reagent contains potassium ferricyanide (K Fe(CN) potassium cyanide (KCN), and sodium bicarbonate (NaI-ICO When the hemoglobin is added to this reagent, the potassium ferricyanide is reduced to potassium ferrocyanide (K,Fe(CN) and the hemoglobin is oxidized to methemoglobin which reacts with cyanide to produce to produce the stable chromogen, cyanmeth-hemoglobin.
  • Drabkins reagent is not stable to low temperature. It has been found that Drabkins reagent, if exposed to freezing temperatures, loses its color with the subsequent loss of accuracy of the hemoglobin determinations made by using the reagent.
  • a typical Drabkins reagent contains 61 X 10' moles of potassium ferricyanide, 77 X moles of potassium cyanide, and l 190 X 10 moles of sodium bicarbonate per liter. This reagent is very stable. It has been reported in the article by Crosby and Houchin published in the Journal, Blood, 12 1136 (1957), that the cyanmeth-hemoglobin when formed in this reagent shows only a 4 percent loss of color when stored in sealed amber bottles for a period of 3 years.
  • the Drabkins reagent is made up and 0.2 to l0 weight percent of acetone is added as a loss of color inhibitor.
  • the addition of acetone to the Drabkins reagent also results in attaining immediate recovery of the peak absorbance of cyanmeth-hemoglobin in using the test.
  • the Drabkins reagent is made up in the conventional manner.
  • a typical formulation contains 200 milligrams potassium ferricyanide, 50 milligrams of KCN, and 1 gram of sodium bicarbonate per liter.
  • the hemoglobin determination is made by the observance of the height of the 540 millimicron peak in a typical spectrophotometer scan of the solution containing the blood sample.
  • the concentration is computed from the following equation:
  • C is the concentration of the unknown and C, is the concentration of the standard, in grams per 100 ml.
  • A is the absorbance of the unknown and A, is the absorbance of the standard.
  • Drabkins reagent was prepared by dissolving 200 milligrams of potassium ferricyanide, 50 milligrams of potassium cyanide, and 1 gram of sodium bicarbonate in a liter of water. The reagents were mixed thoroughly and when dissolved a quantity of acetone equal to 6 ml per liter of solution was added to one portion of this reagent. No acetone was added to the second portion. Both 'of the solutions were then exposed to the temperatures of -20 F for a period of about 96 hours. The solutions were then allowed to warm to room temperatures.
  • test solutions were volumetrically dispensed in 13 X 50 mm. glass cuvettes known as Unitubes. All evaluations were performed using this container as the primary reaction cuvette. All cuvettes had a dispensed volume of 3.8 m1. of Drabkins solution. All whole blood samples were 13 microliters delivered via the Bio-Dynamics Automatic pipette. The cuvettes were then transferred to a model 124 Coleman Spectrophotometer with a 2 millimeter slit. The spectrophotometer was operated at 10 mv full scale. Absorbances of the reagent were measured at the 540 millimicron peak.
  • the height of the peak was essentially the same as the height of the peak using fresh Drabkins solution when the solution used was the solution containing acetone.
  • the height of the peak obtained when the solution used was the Drabkins solution that had been frozen but contained no acetone was only about 30 percent of the height obtained from the same test using fresh Drabkins reagent.
  • EXAMPLE 2 In the process of evaluating the acetone modified reagent prepared according to the procedure described above, a spectral curve was run using a model 124 Coleman Spectrophotometer with a 2 millimeter slit. The spectrophotometer was operated at 10 millivolts full scale. Two separate tests were run. Blanks containing only the reagents were run as a reference. The first test was run using 3.8 ml of a Drabkins reagent that did not contain acetone. The second test was run using 3.8 ml. of Drabkins reagent containing 6 ml of acetone per liter. Both of these tests were run with 13 microliters of blood having normal hemoglobin with a fast scan at 10 minutes to ascertain if secondary reactions have occurred.
  • the test run with the Drabkins reagent that contained no acetone had two characteristic peaks, one appearing at 570 millimicrons and one at 540 millicrons.
  • the 570 millimicron peak is, of course, associated with oxy-hemoglobin.
  • the 540 millimicron peak was obtained immediately. There was no initial peak at 570 millimicrons.
  • the reagent containing the acetone was then run using a 10 minute scan. There was no interference, primary or secondary.
  • the improvement comprising adding about 0.2 to 10 weight percent acetone to said solution to prevent loss of color in said solution on exposure of the solution to temperatures below 32 F and the resultant inaccuracies in the measurement.
  • test solution contains about 61 X 10' moles of potassium ferricyanide, 77 X moles of potassium cyanide and l 190 X 10 moles of sodium bicarbonate per liter.
  • the method of immediately attaining the cyanmeth hemoglobin peak in the spectrophotometric determination of hemoglobin using the cyanmeth-hemoglobin procedure which comprises adding from about 2% to 126 ml of acetone per liter to the reagent used in making the determination.

Abstract

A method of determining hemoglobin in blood using Drabkin''s reagent wherein acetone is added to the reagent as a loss of color inhibitor and to aid in attaining immediate recovery of the peak absorbance of cyanmeth-hemoglobin.

Description

United States Patent Depositar et al.
[ 51 May 16, 1972 METHOD OF DETERMINING HEMOGLOBIN IN BLOOD Edward L. Depositar, Indianapolis; Robert K. Shipley, Muncie; David T. Santore, Indianapolis, all of Ind.
Assignee: Bio-Dynamics, Inc., Indianapolis, Ind.
Filed: Oct. 5, 1970 Appl. No.: 78,159
inventors:
US. Cl ..23/230 B, 252/408 lnt.Cl. ..G0ln 33/16, G0ln3l/22,G0ln 21/24 Field of Search ..23/230; 252/408 Primary Examiner-Morris O. Wolk Assistant Examiner--Eiliott A. Katz AttorneyWoodard, Weikart, Emhardt & N aughton [5 7] ABSTRACT A method of determining hemoglobin in blood using Drabkins reagent wherein acetone is added to the reagent as a loss of color inhibitor and to aid in attaining immediate recovery of the peak absorbance of cyanmeth-hemoglobin.
5 Claims, No Drawings METHOD OF DETERMINING HEMOGLOBIN IN BLOOD BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a method of determining hemoglobin in blood using Drabkins reagent. The reagent contains potassium ferricyanide (K Fe(CN) potassium cyanide (KCN), and sodium bicarbonate (NaI-ICO When the hemoglobin is added to this reagent, the potassium ferricyanide is reduced to potassium ferrocyanide (K,Fe(CN) and the hemoglobin is oxidized to methemoglobin which reacts with cyanide to produce to produce the stable chromogen, cyanmeth-hemoglobin.
2. Background of the Invention This method was first described by Drabkin and Austin in the Journal of Biological Chemistry 98 719, (1932) and was discussed later by the same authors in the Journal of Biological Chemistry 1 12 51 (1935). This procedure is known as the cyanmeth-hemoglobin procedure. Because cyanmethhemoglobin is stable, the procedure is widely used in field tests for hemoglobin. The procedure lends itself to the preparation of Drabkins reagent which can be shipped to the field for use by the physician or the clinical laboratory technicians in specially designed containers to simplify the hemoglobin test.
One of the problems with this procedure, however, is that the Drabkins reagent is not stable to low temperature. It has been found that Drabkins reagent, if exposed to freezing temperatures, loses its color with the subsequent loss of accuracy of the hemoglobin determinations made by using the reagent.
A typical Drabkins reagent contains 61 X 10' moles of potassium ferricyanide, 77 X moles of potassium cyanide, and l 190 X 10 moles of sodium bicarbonate per liter. This reagent is very stable. It has been reported in the article by Crosby and Houchin published in the Journal, Blood, 12 1136 (1957), that the cyanmeth-hemoglobin when formed in this reagent shows only a 4 percent loss of color when stored in sealed amber bottles for a period of 3 years.
The loss of color in this reagent on exposure to freezing temperatures is, of course, a major problem, particularly where the reagent is packaged and made available for field testing for hemoglobin.
SUMMARY OF THE INVENTION In the preferred embodiment of the invention, the Drabkins reagent is made up and 0.2 to l0 weight percent of acetone is added as a loss of color inhibitor. The addition of acetone to the Drabkins reagent also results in attaining immediate recovery of the peak absorbance of cyanmeth-hemoglobin in using the test.
DESCRIPTION OF THE PREFERRED EMBODIMENT The Drabkins reagent is made up in the conventional manner. A typical formulation contains 200 milligrams potassium ferricyanide, 50 milligrams of KCN, and 1 gram of sodium bicarbonate per liter. The hemoglobin determination is made by the observance of the height of the 540 millimicron peak in a typical spectrophotometer scan of the solution containing the blood sample. The concentration is computed from the following equation:
u X s/ where C is the concentration of the unknown and C, is the concentration of the standard, in grams per 100 ml. A is the absorbance of the unknown and A, is the absorbance of the standard.
We have found that when the acetone is added to the Drabkins reagent in the concentrations pointed out above, preferably at 0.6 percent, the freezing point of the Drabkins solution is only slightly depressed. However, even though the reagent is frozen, the yellow color remains and there is no change in optical density of the reagent. This finding obviously solves the long standing problem caused by the loss of the color of Drabkins reagent when exposed to freezing temperatures.
In addition, it was found that the addition of acetone to Drabkins reagent obtained immediate recovery of the peak absorbance in cyanmeth-hemoglobin. This is particularly important in that the characteristic peak at 540 millimicrons is attained immediately with no initial peak at 570 millimicrons (the standard peak for oxy-hemoglobin). The precision of the test is improved since the instantaneous appearances cyanmeth-hemoglobin peak without the appearance of the oxyhemoglobin peak eliminates any possibility of transposing the value of the oxy-hemoglobin reading with the resulting error in the calculation of the percentage hemoglobin in the blood sample.
Our invention is illustrated by the following specific but non-limiting examples.
EXAMPLE 1 Drabkins reagent was prepared by dissolving 200 milligrams of potassium ferricyanide, 50 milligrams of potassium cyanide, and 1 gram of sodium bicarbonate in a liter of water. The reagents were mixed thoroughly and when dissolved a quantity of acetone equal to 6 ml per liter of solution was added to one portion of this reagent. No acetone was added to the second portion. Both 'of the solutions were then exposed to the temperatures of -20 F for a period of about 96 hours. The solutions were then allowed to warm to room temperatures.
The test solutions were volumetrically dispensed in 13 X 50 mm. glass cuvettes known as Unitubes. All evaluations were performed using this container as the primary reaction cuvette. All cuvettes had a dispensed volume of 3.8 m1. of Drabkins solution. All whole blood samples were 13 microliters delivered via the Bio-Dynamics Automatic pipette. The cuvettes were then transferred to a model 124 Coleman Spectrophotometer with a 2 millimeter slit. The spectrophotometer was operated at 10 mv full scale. Absorbances of the reagent were measured at the 540 millimicron peak. The height of the peak was essentially the same as the height of the peak using fresh Drabkins solution when the solution used was the solution containing acetone. In contrast, the height of the peak obtained when the solution used was the Drabkins solution that had been frozen but contained no acetone was only about 30 percent of the height obtained from the same test using fresh Drabkins reagent.
It is obvious from this data that the addition of acetone to the Drabkins reagent provides an effective loss of color inhibitor for the reagent and allows the preparation of a reagent that can be transported without fear of loss of activity due to freezing.
EXAMPLE 2 In the process of evaluating the acetone modified reagent prepared according to the procedure described above, a spectral curve was run using a model 124 Coleman Spectrophotometer with a 2 millimeter slit. The spectrophotometer was operated at 10 millivolts full scale. Two separate tests were run. Blanks containing only the reagents were run as a reference. The first test was run using 3.8 ml of a Drabkins reagent that did not contain acetone. The second test was run using 3.8 ml. of Drabkins reagent containing 6 ml of acetone per liter. Both of these tests were run with 13 microliters of blood having normal hemoglobin with a fast scan at 10 minutes to ascertain if secondary reactions have occurred.
The test run with the Drabkins reagent that contained no acetone had two characteristic peaks, one appearing at 570 millimicrons and one at 540 millicrons. The 570 millimicron peak is, of course, associated with oxy-hemoglobin. When the same scan was run using the acetone modified Drabkins reagent, the 540 millimicron peak was obtained immediately. There was no initial peak at 570 millimicrons. The reagent containing the acetone was then run using a 10 minute scan. There was no interference, primary or secondary.
It is obvious from these data that the Drabkins reagent containing acetone gives an instantaneous cyanmeth-hemoglobin reading and eliminates the possibility of error to transposition of the oxy-hemoglobin reading from the spectrophotometer chart before the cyanmeth-hemoglobin appears.
What is claimed is:
1. In the determination the hemoglobin content of blood using the cyanmeth-hemoglobin method in which potassium cyanide, potassium ferricyanide and sodium bicarbonate are the active ingredients in the solution used to make the determination, the improvement comprising adding about 0.2 to 10 weight percent acetone to said solution to prevent loss of color in said solution on exposure of the solution to temperatures below 32 F and the resultant inaccuracies in the measurement.
2. The method according to claim 1 wherein the test solution contains about 61 X 10' moles of potassium ferricyanide, 77 X moles of potassium cyanide and l 190 X 10 moles of sodium bicarbonate per liter.
3. The method of inhibiting loss of color in a hemoglobin test solution containing about 61 X 10 moles of potassium ferricyanide, 77 X 10 moles of potassium cyanide and 1,190 X 10" moles of sodium bicarbonate per liter, on exposure of said solution to temperatures below 32 F which comprises adding 0.2 to 10 weight percent acetone to said solution.
4. In the determination of the hemoglobin content of blood using a solution containing potassium cyanide, potassium ferricyanide and sodium bicarbonate in which the potassium ferricyanide is reduced to potassium ferrocyanide the improvement comprising adding from 0.2 to 10 weight percent acetone to said solution to assure immediate attainment of the peak absorbance of cyanmeth-hemoglobin in the spectrophotometric determination of the hemoglobin of blood sample.
5. The method of immediately attaining the cyanmeth hemoglobin peak in the spectrophotometric determination of hemoglobin using the cyanmeth-hemoglobin procedure which comprises adding from about 2% to 126 ml of acetone per liter to the reagent used in making the determination.

Claims (4)

  1. 2. The method according to claim 1 wherein the test solution contains about 61 X 10 5 moles of potassium ferricyanide, 77 X 10 5 moles of potassium cyanide and 1190 X 10 5 moles of sodium bicarbonate per liter.
  2. 3. The method of inhibiting loss of color in a hemoglobin test solution containing about 61 X 10 5 moles of potassium ferricyanide, 77 X 10 5 moles of potassium cyanide and 1,190 X 10 5 moles of sodium bicarbonate per liter, on exposure of said solution to temperatures below 32* F which comprises adding 0.2 to 10 weight percent acetone to said solution.
  3. 4. In the determination of the hemoglobin content of blood using a solution containing potassium cyanide, potassium ferricyanide and sodium bicarbonate in which the potassium ferricyanide is reduced to potassium ferrocyanide the improvement comprising adding from 0.2 to 10 weight percent acetone to said solution to assure immediate attainment of the peak absorbance of cyanmeth-hemoglobin in the spectrophotometric determination of the hemoglobin of blood sample.
  4. 5. The method of immediately attaining the cyanmeth hemoglobin peak in the spectrophotometric determination of hemoglobin using the cyanmeth-hemoglobin procedure which comprises adding from about 2 1/2 to 126 ml of acetone per liter to the reagent used in making the determination.
US78159A 1970-10-05 1970-10-05 Method of determining hemoglobin in blood Expired - Lifetime US3663175A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7815970A 1970-10-05 1970-10-05

Publications (1)

Publication Number Publication Date
US3663175A true US3663175A (en) 1972-05-16

Family

ID=22142298

Family Applications (1)

Application Number Title Priority Date Filing Date
US78159A Expired - Lifetime US3663175A (en) 1970-10-05 1970-10-05 Method of determining hemoglobin in blood

Country Status (5)

Country Link
US (1) US3663175A (en)
JP (1) JPS5130796B1 (en)
CA (1) CA952799A (en)
DE (1) DE2149763C3 (en)
GB (1) GB1301635A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3874852A (en) * 1974-07-05 1975-04-01 Coulter Diagnostics Inc Reagent and method for determining leukocytes and hemoglobin in the blood
US3950133A (en) * 1971-10-20 1976-04-13 Mallinckrodt, Inc. Reagent formulations for assaying biological specimens and methods of preparing and using same
US4077772A (en) * 1977-05-31 1978-03-07 Baxter Travenol Laboratories, Inc. Method for the determination of hemoglobin in trace amounts
US4349351A (en) * 1980-07-01 1982-09-14 Bayer Aktiengesellschaft Reagent for the determination of haemoglobin
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4543336A (en) * 1982-02-12 1985-09-24 Dragerwerk Aktiengesellschaft Indicator for determining sulfur dioxide
US4725555A (en) * 1986-10-22 1988-02-16 Helena Laboratories Corporation Zinc protoporphyrin test system
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52141392A (en) * 1976-05-21 1977-11-25 Mitsui Miike Machinery Co Ltd Process and apparatus for intermittent throwing of baits for fish culture

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940448A (en) * 1957-04-29 1960-06-14 Jr Norman B Furlong Disposable blood-gas analyzer
US3427135A (en) * 1966-07-11 1969-02-11 Technicon Instr Hematology apparatus
US3519572A (en) * 1966-10-03 1970-07-07 Pfizer & Co C Blood control
US3546131A (en) * 1968-07-05 1970-12-08 Uni Tech Chem Mfg Co Stabilized cyanmethemoglobin reagent containing ferricyanide,cyanide and polyvinylpyrrolidone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940448A (en) * 1957-04-29 1960-06-14 Jr Norman B Furlong Disposable blood-gas analyzer
US3427135A (en) * 1966-07-11 1969-02-11 Technicon Instr Hematology apparatus
US3519572A (en) * 1966-10-03 1970-07-07 Pfizer & Co C Blood control
US3546131A (en) * 1968-07-05 1970-12-08 Uni Tech Chem Mfg Co Stabilized cyanmethemoglobin reagent containing ferricyanide,cyanide and polyvinylpyrrolidone

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950133A (en) * 1971-10-20 1976-04-13 Mallinckrodt, Inc. Reagent formulations for assaying biological specimens and methods of preparing and using same
US3874852A (en) * 1974-07-05 1975-04-01 Coulter Diagnostics Inc Reagent and method for determining leukocytes and hemoglobin in the blood
US4077772A (en) * 1977-05-31 1978-03-07 Baxter Travenol Laboratories, Inc. Method for the determination of hemoglobin in trace amounts
US4349351A (en) * 1980-07-01 1982-09-14 Bayer Aktiengesellschaft Reagent for the determination of haemoglobin
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4543336A (en) * 1982-02-12 1985-09-24 Dragerwerk Aktiengesellschaft Indicator for determining sulfur dioxide
US6268162B1 (en) 1986-08-13 2001-07-31 Lifescan, Inc. Reflectance measurement of analyte concentration with automatic initiation of timing
US6881550B2 (en) 1986-08-13 2005-04-19 Roger Phillips Method for the determination of glucose employing an apparatus emplaced matrix
US5563042A (en) * 1986-08-13 1996-10-08 Lifescan, Inc. Whole blood glucose test strip
US5843692A (en) * 1986-08-13 1998-12-01 Lifescan, Inc. Automatic initiation of a time interval for measuring glucose concentration in a sample of whole blood
US6887426B2 (en) 1986-08-13 2005-05-03 Roger Phillips Reagents test strip adapted for receiving an unmeasured sample while in use in an apparatus
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US6858401B2 (en) 1986-08-13 2005-02-22 Lifescan, Inc. Minimum procedure system for the determination of analytes
US6821483B2 (en) 1986-08-13 2004-11-23 Lifescan, Inc. Reagents test strip with alignment notch
US20030073153A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system for the determination of analytes
US20030073151A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system
US4725555A (en) * 1986-10-22 1988-02-16 Helena Laboratories Corporation Zinc protoporphyrin test system
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6979571B2 (en) 1999-11-24 2005-12-27 Home Diagnostics, Inc. Method of using a protective test strip platform for optical meter apparatus
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US7390665B2 (en) 2001-02-28 2008-06-24 Gilmour Steven B Distinguishing test types through spectral analysis

Also Published As

Publication number Publication date
GB1301635A (en) 1973-01-04
DE2149763B2 (en) 1973-03-01
CA952799A (en) 1974-08-13
DE2149763C3 (en) 1973-09-13
JPS5130796B1 (en) 1976-09-02
DE2149763A1 (en) 1972-04-06

Similar Documents

Publication Publication Date Title
Wybenga et al. Manual and automated methods for urea nitrogen measurement in whole serum
Russell The colorimetric estimation of small amounts of ammonia by phenol: itypochlorite reaction
US3663175A (en) Method of determining hemoglobin in blood
Foster et al. A single-reagent manual method for directly determining urea nitrogen in serum
US3964865A (en) Lyophilized human hemoglobin standard for colorimetric determination of total hemoglobin
US3986834A (en) Method for detecting blood urea nitrogen
US4078892A (en) Novel means and method for diagnostic quantitation of serum or plasma bilirubin
Kum-Tatt et al. A new colorimetric method for the determination of glutathione in erythrocytes
US3934977A (en) Reagent and method for determining total calcium in body fluids
US4448889A (en) Fluid analysis
US3890099A (en) Colorimetric assay for urea
Rodkey et al. Effects of carboxyhemoglobin on the determination of methemoglobin in blood
USRE26125E (en) Reagents and analysis of nitrogen
US4650752A (en) Method for determining the freshness of fish and mollusks
Cox et al. The measurement of dehydroascorbic acid and diketogulonic acid in normal and diabetic plasma
US3778384A (en) Diagnostic composition for the quantitative determination of glucose
Bruce et al. Two-point determination of plasma ammonia with the centrifugal analyzer.
EP0061793B1 (en) Method for preparing a chromogen reactive for determining the serum iron concentration and binding power, and the chromogen reactive obtained thereby
Asp Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent
US4030885A (en) Bilirubin determination
da Fonseca-Wollheim Haemoglobin interference in the bichromatic spectrophotometry of NAD (P) H at 340/380 nm
Radin et al. Differential spectrophotometric determination of calcium
Bradbury A simplified method for the estimation of sodium
US3754862A (en) Reagnet composition and method for determining total bilirubin
US3807956A (en) Modified biuret reagent for glass storage and method

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER MANNHEIM DIAGNOSTICS, INC., 9115 HAGUE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BIO-DYNAMICS, INC.;REEL/FRAME:004239/0504

Effective date: 19831028

AS Assignment

Owner name: BOEHRINGER MANNHEIM CORPORATION, A CORP. OF NEW YO

Free format text: CHANGE OF NAME;ASSIGNOR:BOEHRINGER MANNHEIM DIAGNOSTICS, INC. A CORP. OF DE.;REEL/FRAME:004624/0055

Effective date: 19861008

AS Assignment

Owner name: BOEHRINGER MANNHEIM CORPORATION

Free format text: MERGER;ASSIGNOR:BOEHRINGER MANNHEIM CORPORATION, A NY CORP.;REEL/FRAME:004912/0770

Effective date: 19870625

Owner name: BOEHRINGER MANNHEIM CORPORATION, A IN CORP.

Free format text: MERGER;ASSIGNOR:BOEHRINGER MANNHEIM CORPORATION, A NY CORP.;REEL/FRAME:004912/0770

Effective date: 19870625